Product imageResearch use only

CAT. NO. DC60509Featured

4A3-SCC-PH

Pack size & price

USD

Add the cited formulation componentsSelected 4A3-SCC-PH pack + every supporting component at 100 mg each+US$450 / set

Supporting components

DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$600

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

4A3-SCC-PH is a biodegradable ionizable lipid investigated for liver-directed mRNA delivery. Published mouse studies report enhanced luciferase expression and extensive Cre-mediated reporter activation in hepatocytes. The detailed evidence includes formulation composition, cellular delivery, liver expression, imaging applications and tolerability.

Open full Formulation & Performance →

Literature evidence · DC60509

Formulation & Performance

The 2023 JACS study separates luciferase expression, Cre reporter activation and metastatic-lesion imaging. These are distinct endpoints; the reported 99% hepatocyte result is a Cre/tdTomato reporter readout.

DC60509 corresponds to 4A3-SCC-PH. Results from 4A3-SCC-10, 4A3-SC-PH and 4A3-SSC-PH are comparator results and are not reassigned to this product.

Formulation components and molecular-weight conversion

Component	DC Chemicals product	Molecular weight	Molar ratio	Mass at 1 µmol total lipid (mg)
4A3-SCC-PH	DC60509	1948.094	15	0.463832
DOPE	DC33634	744.03	15	0.177150
Cholesterol	DCD-041	386.65	30	0.184119
DMG-PEG2000	DC40169	2507	3	0.119381

Source: main text and Supporting Information, LNP formulation and pKa sections. The reported 15:15:30:3 values are relative molar parts (sum 63), not mol%. Mass conversion normalizes this sum. The SI describes 40:1 using the ambiguous phrase “weight molar”; it is not treated here as a verified N/P or lipid:RNA mass ratio. DMG-PEG2000 uses MW 2507.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

Total lipid (µmol)

Component	Mass (mg)	Mass %
4A3-SCC-PH	—	—
DOPE	—	—
Cholesterol	—	—
DMG-PEG2000	—	—

Formulation and particle characterization

Study / parameter	Reported evidence	Source / interpretation
Four-component LNP	4A3-SCC-PH / DOPE / cholesterol / DMG-PEG2000 = 15:15:30:3	Main text; SI formulation section, printed p.29
RNA association	Gel-retardation and reducing-condition release assays are reported	SI Fig. S4; no numerical encapsulation percentage assigned
Particle properties	DLS size, zeta potential and PDI are presented graphically	SI Fig. S3; numerical batch specifications are not inferred from bars
Stored formulated LNP	Luciferase delivery remained measurable after one month at 4 or −20 °C	SI Fig. S16; a formulated-LNP experiment, not a pure-lipid shelf-life claim

Cellular expression and intracellular delivery

Study / parameter	Reported evidence	Source / interpretation
IGROV1 luciferase assay	25 ng mRNA/well; 24 h; n = 4; 15.5-fold higher expression than MC3 reported	Main Fig. 3a and SI cell-assay methods
mCherry expression	80 ng mRNA/well; fluorescence imaging and flow cytometry supported improved expression	Main Fig. 3b–c; do not substitute this dose for the luciferase assay
Uptake versus expression	Similar cellular uptake among tested LNPs, with different expression outputs	SI Fig. S6; uptake alone did not explain potency
Endosomal escape	HeLa colocalization experiments at 4 and 8 h supported improved escape	Main Fig. 4g; assay-specific mechanistic evidence, not a universal escape percentage

Mouse liver expression and reporter activation

Study / parameter	Reported evidence	Source / interpretation
Luciferase expression	C57BL/6 mice; intravenous 0.1 mg/kg mRNA; 6 h; n = 3; 176-fold liver signal versus MC3	Main Fig. 3g–h; study-specific signal ratio
Matched structural comparators	65-fold versus 4A3-SC-PH and 14-fold versus 4A3-SSC-PH in the reported liver experiment	Main Fig. 3h; distinct compounds
Cre reporter	Intravenous 0.2 mg/kg Cre mRNA; analysis at 2 days; n = 3	Main Fig. 5d–f; SI Fig. S18 and in vivo methods
Reported hepatocyte response	Approximately 99% tdTomato-positive hepatocytes	Cre-mediated stop-cassette removal; not a Cas9 indel frequency or disease correction rate

Biological imaging application

Study / parameter	Reported evidence	Source / interpretation
Experimental use	Fluc mRNA delivery was used to illuminate experimental metastatic lesions	Main Fig. 6; breast-cancer and melanoma models
Dose context	Reported imaging experiments used 0.1 mg/kg Fluc mRNA	Main Fig. 6 caption; check the panel-specific collection time
Readout	Bioluminescence and ex vivo tissue observations supported lesion delineation	An imaging endpoint, not tumor shrinkage or survival benefit
Interpretation	Reporter localization and expression were evaluated together with tumor/normal cell comparisons	Main Fig. 6; SI Figs. S20–S22

Tolerability and limits of the evidence

Study / parameter	Reported evidence	Source / interpretation
Cell viability	No obvious loss of IGROV1 viability under the tested mRNA-LNP conditions	SI Figs. S1 and S5; no IC50 is assigned
Mouse observations	No distinct body-weight loss or obvious organ damage reported in the tested study	SI Fig. S17; histology and weight endpoints
Hemolysis context	Membrane-disruption assays differed between acidic and physiological pH	Main Fig. 4e–f and SI Fig. S13; acidic assay activity is not systemic safety
Evidence boundary	No primate or human efficacy, repeated-dose NOAEL, or batch-specific performance is established here	Use the reported mouse/cell endpoints within their study context

Original study figures

Main Figs. 3, 5 and 6: cellular delivery, liver reporter activation and biological imaging — Original source figures.

Supporting Figs. S3–S5 and S16–S18: particle properties, viability, stability and tolerability — Original source figures.

References and source locations

CAS No.	Not available
Chemical Name	4A3-SCC-PH
Synonyms	4A3-SCC-PH; 4A3 SCC PH; 4A3-SCC PH; 4A3 SCC-PH
SMILES	CN(CCCN(CCC(OCCSSCCOC(C(C)CSCC(CCC)CCCCC)=O)=O)CCC(OCCSSCCOC(C(C)CSCC(CCC)CCCCC)=O)=O)CCCN(CCC(OCCSSCCOC(C(C)CSCC(CCC)CCCCC)=O)=O)CCC(OCCSSCCOC(C(C)CSCC(CCC)CCCCC)=O)=O
Formula	C91H171N3O16S12
M.Wt	1948.094
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Chen Z et al. Modular Design of Biodegradable Ionizable Lipids for Improved mRNA Delivery and Precise Cancer Metastasis Delineation In Vivo. JACS 145, 24302–24314 (2023). DOI: 10.1021/jacs.3c09143. Supporting Information: formulation, cell and animal methods; Figs. S1–S22.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

The reported molar ratio totals 63; normalized only for component mass calculation. N/P remains unreported.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	5.1332 mL	1.0266 mL	513.32 μL
25 mg	12.8331 mL	2.5666 mL	1.2833 mL
50 mg	25.6661 mL	5.1332 mL	2.5666 mL
100 mg	51.3322 mL	10.2664 mL	5.1332 mL
250 mg	128.3306 mL	25.6661 mL	12.8331 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

4A3-SCC-PH

Pack size & price

Description & Application

Recommended Products

E10i-494

LP-01

SM-86(Lipid 5)

ALC-0315

CKK-E12

5A2-SC8

OF-02

FTT5

246C10

SM-102